{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:43:35Z","timestamp":1784313815079,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.006","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T13:28:12Z","timestamp":1364304492000},"page":"936-941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Novel future therapeutic options in Myasthenia Gravis"],"prefix":"10.1016","volume":"12","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.03.006_bb0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1749-6632.2012.06832.x","article-title":"Biologics and other novel approaches and new therapeutic options in myasthenia gravis: a view to the future","volume":"1274","author":"Dalakas","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.autrev.2013.03.006_bb0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/08916930410001708751","article-title":"Myasthenia gravis","volume":"37","author":"Vincent","year":"2004","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.006_bb0275","first-page":"1769","article-title":"Acquired autoimmune myasthenia gravis","author":"Engel","year":"2006"},{"key":"10.1016\/j.autrev.2013.03.006_bb0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0072-9752(07)01508-4","article-title":"Therapy of myasthenia gravis","volume":"91","author":"Drachman","year":"2008","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2013.03.006_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","article-title":"Antigen-specific immunotherapy of autoimmune and allergic diseases","volume":"22","author":"Sabatos-Peyton","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1196\/annals.1405.023","article-title":"Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis","volume":"1132","author":"Meriggioli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"5\u20136","key":"10.1016\/j.autrev.2013.03.006_bb0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.006_bb0315","series-title":"Myasthenia gravis: mechanisms of disease and immune intervention","first-page":"89","article-title":"Evidence-based efficacy of intravenous immunoglogulin in human myasthenia gravis and mechanisms of action","author":"Dalakas","year":"2010"},{"issue":"1","key":"10.1016\/j.autrev.2013.03.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002277.pub3","article-title":"Intravenous immunoglobulin for myasthenia gravis","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.autrev.2013.03.006_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ana.23538","article-title":"Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica","volume":"71","author":"Steinman","year":"2012","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2013.03.006_bb0055","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.006_bb0060","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.autrev.2013.03.009","article-title":"Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model","volume":"12","author":"Gertel-Lapter","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2013.03.006_bb0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11940-011-0119-8","article-title":"Immunotherapy of inflammatory myopathies: practical approach and future prospects","volume":"13","author":"Dalakas","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nmd.2005.12.008","article-title":"Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future","volume":"16","author":"Dalakas","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2013.03.006_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-41139","article-title":"Basic principles of immunotherapy in neurological diseases","volume":"23","author":"Hohlfeld","year":"2003","journal-title":"Sem Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2013.03.006_bb0085","first-page":"129","article-title":"Immunotherapy of myositis: issues, concerns future prospects nature review","volume":"6","author":"Dalakas","year":"2010","journal-title":"Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.006_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2011.121","article-title":"Advances in the diagnosis, pathogenesis and treatment of CIDP","volume":"7","author":"Dalakas","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0095","first-page":"107","article-title":"Signal transduction in T lymphocytes","volume":"17","author":"Peterson","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(00)02473-9","article-title":"Sirolimus and cyclosporin for renal transplantation","volume":"356","author":"Halloran","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.006_bb0105","doi-asserted-by":"crossref","unstructured":"Tak PL, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 25;13 Suppl 1:S5.","DOI":"10.1186\/1478-6354-13-S1-S5"},{"key":"10.1016\/j.autrev.2013.03.006_bb0110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00001622-200011000-00010","article-title":"Campath-1H monoclonal antibody therapy","volume":"12","author":"Flynn","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0285","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"The CAMMS223 Trial Investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2013.03.006_bb0120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"issue":"22","key":"10.1016\/j.autrev.2013.03.006_bb0290","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.006_bb0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(10)70033-8","article-title":"Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta","volume":"9","author":"Wynn","year":"2011","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2013.03.006_bb0135","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2013.03.006_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2013.03.006_bb0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.006_bb0150","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1212\/01.wnl.0000313840.27060.bf","article-title":"Inhibition of B cell, functions: implications for neurology","volume":"70","author":"Dalakas","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.autrev.2013.03.006_bb0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"10","key":"10.1016\/j.autrev.2013.03.006_bb0160","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","article-title":"A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis","volume":"65","author":"Ragheb","year":"2008","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.006_bb0165","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B cell therapy in Myasthenia Gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.006_bb0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.autrev.2013.03.006_bb0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1756285609356135","article-title":"Practical considerations on the use of rituximab in autoimmune neurological disorders","volume":"3","author":"Kosmidis","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.autrev.2013.03.006_bb0295","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2013.03.006_bb0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2013.03.006_bb0190","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1172\/JCI58743","article-title":"Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity","volume":"122","author":"Maurer","year":"2012","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.autrev.2013.03.006_bb0300","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.autrev.2013.03.006_bb0200","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2013.03.006_bb0205","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2013.03.006_bb0210","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1084\/jem.20062545","article-title":"Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program","volume":"204","author":"Dhodapkar","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.006_bb0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.autrev.2013.03.006_bb0305","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.006_bb0310","first-page":"1365","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"10","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2013.03.006_bb0230","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.autrev.2013.03.006_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000045663","article-title":"Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm\u2013Horsfall glycoprotein in urine of patients with active lupus nephritis","volume":"85","author":"Tsai","year":"2000","journal-title":"Nephron"},{"issue":"13","key":"10.1016\/j.autrev.2013.03.006_bb0240","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2013.03.006_bb0245","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.006_bb0250","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2013.03.006_bb0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clim.2008.03.509","article-title":"Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis","volume":"128","author":"Sheng","year":"2008","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2013.03.006_bb0260","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285612450936","article-title":"Current and emerging therapies in multiple sclerosis: a systematic review","volume":"5","author":"Castro-Borrero","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.autrev.2013.03.006_bb0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.006_bb0270","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","article-title":"Enzymatic deglycosylation convers pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin g into therapeutic antibody","volume":"73","author":"Tradtrantip","year":"2013","journal-title":"Ann Neurol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T10:41:16Z","timestamp":1595587276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1568997213000323"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.006","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel future therapeutic options in Myasthenia Gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}